cookies-img
We use third-party cookies to provide support. By continuing to browse this website, you accept our privacy policy.
close-icon
Point Biopharma Global Inc
2 own
3 watching
Current Price
$0
$0.3
(2.97%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Market Capitalization
Market Capitalization
1,068.12M
52-Week High
52-Week High
11.13
52-Week Low
52-Week Low
5.59
Average Volume
Average Volume
0.07M
Dividend Yield
Dividend Yield
--
P/E Ratio
P/E Ratio
--
iconMarket Capitalization1,068.12M
icon52-Week High11.13
icon52-Week Low5.59
iconAverage Volume0.07M
iconDividend Yield--
iconP/E Ratio--
What does the Point Biopharma Global Inc do?
POINT Biopharma Global Inc., a radiopharmaceutical company, focuses on the development and commercialization of radioligands that fight cancer. Its lead product candidates include PNT2002, a prostate-specific membrane antigen (PSMA) targeted radioligand that is in Phase III trial for the treatment of metastatic castration-resistant prostate cancer; and PNT2003, a somatostatin-targeted radioligand, which is in Phase III trial for the treatment of neuroendocrine tumors. The company is also developing PNT2001, a next-generation PSMA-targeting product candidate for the treatment of non-metastatic castration sensitive prostate cancer, which is under preclinical studies; and PNT-2004, a fibroblast activation protein-a targeting program being developed for use in multiple tumor types that is under preclinical studies. In addition, it has product candidates being developed on CanSEEK technology sub-licensed from both Bach Biosciences LLC and Avacta Life Sciences Limited. POINT Biopharma Global Inc. was founded in 2019 and is headquartered in Indianapolis, Indiana.
Read More
How much money does Point Biopharma Global Inc make?
News & Events about Point Biopharma Global Inc.
Zolmax
1day ago
POINT Biopharma Global Inc. (NASDAQ:PNT Get Rating) has been assigned a consensus recommendation of Buy from the nine research firms that are covering the firm, Marketbeat.com reports. Six research analysts have rated the stock with a buy rating. The average 1 year price target...
Globe Newswire
2 months ago
Signed Strategic Collaboration Agreement with Lantheus Holdings Inc. for POINT's PNT2002 and PNT2003 product candidates Completed enrollment for randomization phase of PNT2002's phase 3 SPLASH registrational trial, with top line data expected in the second half of 2023 INDIANAPOLIS, March 27, 2023 (...
Market News Video
4 months ago
In trading on Monday, shares of POINT Biopharma Global Inc (PNT) crossed below their 200 day moving average of 7.78, changing hands as low as 7.67 per share. POINT Biopharma Global Inc shares are currently trading down about 1.4% on the day...
Zolmax
4 months ago
Shares of POINT Biopharma Global Inc. (NASDAQ:PNT Get Rating) have earned a consensus rating of Buy from the ten analysts that are presently covering the stock, Marketbeat reports. Seven investment analysts have rated the stock with a buy rating. The average 1-year price target among brokerages that...
Globe Newswire
4 months ago
INDIANAPOLIS, Feb. 02, 2023 (GLOBE NEWSWIRE) -- POINT Biopharma Global Inc. (NASDAQ: PNT) (the Company or POINT), a company accelerating the discovery, development, and global access to life-changing radiopharmaceuticals, today announced management will participate in the following upcoming investor...
Frequently Asked Questions
Frequently Asked Questions
What is Point Biopharma Global Inc share price today?
plus_minus_icon
Can Indians buy Point Biopharma Global Inc shares?
plus_minus_icon
How can I buy Point Biopharma Global Inc shares from India?
plus_minus_icon
Can Fractional shares of Point Biopharma Global Inc be purchased?
plus_minus_icon
What are the documents required to start investing in Point Biopharma Global Inc stocks?
plus_minus_icon
What is today’s traded volume of Point Biopharma Global Inc?
plus_minus_icon
What is today’s market capitalisation of Point Biopharma Global Inc?
plus_minus_icon
What is the 52-Week High and Low Range of Point Biopharma Global Inc?
plus_minus_icon
What percentage is Point Biopharma Global Inc down from its 52-Week High?
plus_minus_icon
What percentage is Point Biopharma Global Inc up from its 52-Week Low?
plus_minus_icon
Current Price
$0
$0.3
(2.97%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Related Stocks
Sign up and dive into a whole new world of investing.
Join over 370,000 who have signed up and are using Stockal successfully already.
Related Stocks
Sign up and dive into a whole new world of investing.
Join over 370,000 who have signed up and are using Stockal successfully already.

              Borderless Investing Inc., (“Borderless Investing”), the owner of the Stockal Platform, is not a broker-dealer nor an investment advisor and through its affiliate stockbroker Stockal Securities Pvt. Ltd., (SEBI INZ000301236), acting as the introducing entity has entered into a clearing agreement with DriveWealth LLC., to offer U.S. equities on the Stockal Platform. The Stockal Platform enables investments in a diverse set of global assets from a single account from anywhere in the world. As such, Borderless Investing makes no warranties or representations, express or implied, on products and services offered through its website/platform. It accepts no liability for any damages or losses, however, caused in connection with the use of related services.

              All investments involve risk and returns will fluctuate, are subject to market volatility and may cause losses. The material on this website/platform is provided solely for informational and educational purposes and shall not in any manner be considered a recommendation or endorsement of any strategy or investment, nor an offer to sell or a solicitation of an offer to buy securities, products or services nor advice. Borderless Investing makes no guarantee as to the currency, accuracy, or quality of information published and/or archived on this website/platform, nor will Borderless Investing accept any responsibility for other organizations, businesses, and private persons that provide information on this website/platform. All information on this website/platform regarding products and services provided by Borderless Investing is subject to change without notice. Reasonable efforts are taken to ensure the accuracy and integrity of all information provided here, but Borderless Investing is not responsible for misprints, out of date information, or errors. Any investment decision and/or strategy that investors make or employ, whether or not such decision or strategy derives from or relies upon material accessed or provided through this website/platform, is undertaken at the investor’s sole discretion and risk. Before making any investment decisions, investors should consult additional sources of information and/or their legal or tax advisor. PLEASE READ THIS FULL DISCLOSURE CAREFULLY BEFORE USING THIS SERVICE. BY USING THE SERVICE OR CLICKING AGREE YOU ARE AGREEING TO BE BOUND BY THESE DISCLOSURES AND ALL TERMS AND CONDITIONS ON THIS WEBSITE/PLATFORM.

              *DriveWealth LLC., a member of the Securities Investor Protection Corporation (SIPC), will serve as the custodian for your securities account. In the event that DriveWealth LLC., fails and is placed in liquidation under the Securities Investor Protection Act, securities in your brokerage account may be protected up to $500,000. For details, please see www.sipc.org.

              All brands and logos used on this website are the property of their respective owners.

              Get Started with as little as $1.00